Skip to content
DraconiticResearch
Search Sources API
186,546 studies31 sourcesUpdated 25 min ago
Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research

Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study

Read full textPDFCite

Related

  1. Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup
    Jin-Yuan Shih, Jie Wang, Yongsheng Wang +15
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Synergistic efficacy of the EGFR inhibitor osimertinib with the XPO1 inhibitor selinexor in T-cell acute lymphoblastic leukemia.
    Rushuang Xu, Xiangtao Huang, Jia Liu +6
    Biomarker researchPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMCPMC
  3. Successful Alternate-day Osimertinib Administration with Desensitization Following Osimertinib-induced Hepatotoxicity and Neutropenia in a Case of EGFR-mutant Lung Cancer
    Tatsuo Furuya, Satoru Okada, Masanori Shimomura +2
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineJ-STAGE
  4. High PD-L1 Expression and Clinical Outcomes of First-Line Osimertinib in EGFR-Mutant NSCLC: A Multicenter Real-World Validation Study (WJOG 20724L)
    Yoshihiko Sakata, Kenta Murotani, Daichi Fujimoto +18
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  5. DRESS during chemotherapy with carboplatin, pemetrexed, and osimertinib for lung adenocarcinoma: A case report
    Naoki Okada, Hiroto Takiguchi, Atsushi Ito +10
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedPharmacology & toxicologyJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{anon2026efficacy,
  title = {{Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study}},
  journal = {Translational Lung Cancer Research},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13657886},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Efficacy and safety of osimertinib combined with anlotinib in EGFR-mutant non-squamous non-small cell lung cancer with gradual progression after first-line osimertinib therapy: a single-center retrospective cohort study
PY  - 2026
DA  - 2026/09/23
JO  - Translational Lung Cancer Research
UR  - https://europepmc.org/article/PMC/PMC13657886
SN  - 2218-6751
ER  -